Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2012

View Archived Issues

Researchers at Lycera prepare new F1F0 ATPase inhibitors

Bristol-Myers Squibb patents new agents for HIV infection

Japanese team discloses novel treatments for diabetes

New EFNA modulators designed by Stem CentRx

New fusion protein from Bristol-Myers Squibb demonstrates antidiabetic activity

Bracco designs novel vaccines for allergy

New D3/5-HT2A receptor modulators patented by Roche

Belgian group discloses novel treatments for neurodegenerative disorders

NPS-1034 shows promise in EGFR-mutant cancer models

Grifols invests in biotechnology firm

CHF-5074 is well tolerated in patients with mild cognitive impairment

GlobeImmune patents novel vaccines for Ad-36 infection and obesity

Alnylam and Ascletis enter collaboration

GlaxoSmithKline withdraws supplemental NDA for Tykerb

Intranasal CP-024 leads to IGF-I induction in healthy volunteers

SEMA7A may have potential as a therapeutic target in breast cancer

Neupro launched in U.S. for Parkinson's disease and RLS

GSK and Theravance file applications for combination COPD candidate

Topline results expected early from phase IIb study of vigabatrin

Tissue Therapies obtains CE Mark for VitroGro ECM wound care product

OncoGenex provides update on phase III development of anticancer candidate

Supernus clarifies tentative approval conditions for Trokendi XR

In vivo results for ARRY-981 presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...